Tagged with China

Roundup A roundup of the latest news from Chinese biotechs, including a bumper IPO for Legend Biotech, a USD two million tie-up between Roche and Innovent Biologics, and a new Alphamab-Sanofi collaboration on KN026 in HER2+ Breast Cancer.   Fresh off ASCO myeloma data, Legend Bio gets USD 424 million in…

China Johnson & Johnson’s network of healthcare innovation incubators, JLABS, opened its doors in Shanghai in June 2019 and now stands as the largest such institution of 13 globally. JLABS @ Shanghai’s head, Dr Sharon Chan, recently sat down with PharmaBoardroom to explain the JLABS model, how it has had to…

China Pierre A Morgon, SVP International Business for CanSino Biotechnology (CanSinoBIO) – a Chinese vaccine biotech developing one of the frontrunner COVID-19 vaccine candidates – shares how his extensive international career brought him to CanSinoBIO, the deeply-rooted public health orientation of the vaccines sector, the complex realities of developing and deploying…

Coronavirus Highly potent neutralizing antibodies may be the key to laying a foundation for COVID-19 treatment, according to a Chinese research team led by Peking University.    The worldwide race against the clock to develop an effective coronavirus vaccine has been underway since early 2020. University research teams, public and private…

China A roundup of some of the top stories in China’s healthcare and life sciences industry, including challenges for Chinese biotechs in the post-pandemic era, why the country needs a biosecurity law, and Chinese companies’ vital role in manufacturing vaccine-related products.   Why does China need a biosecurity law? https://news.cgtn.com/news/2020-05-27/Why-does-China-need-a-biosecurity-law–QQ3wbQcxTG/index.html China…

Hong Kong Alex Zhavoronkov, CEO of Insilico Medicine, lifts the lid on the role of AI in target discovery, identification, and validation. He also offers his opinion on the future of innovative drug development in China, and the challenges of establishing a biotech company in Hong Kong.   Our research within AI…

China Dr Joan Shen, CEO of I-Mab Biopharma, shares her impressive career journey across companies like Pfizer, Janssen and Jiangsu Hengrui, before joining I-Mab, as well as introducing what I-Mab 2.0 might look like for the NASDAQ-listed biotech, their clinical pipeline and her leadership philosophy.   Fundamentally, we need to keep…

Hong Kong Dr Desmond Hau, CEO of Pangenia Inc, sits down with PharmaBoardroom to shed light on the company’s progress since taking the reins three years ago. Hau also explains Pangenia’s strategy to develop their brand in South East Asia, the changes he foresees for the industry post the COVID-19 pandemic, and…

Roundup A roundup of the latest news in Chinese pharma, including a US IPO for Burning Rock Biotech, positive news on CanSino’s COVID-19 vaccine trials, and WuXi Biologics’s first US facility.   Pandemic Exposes Perils of Global Reliance on China for Drug Supplies https://www.voanews.com/science-health/pandemic-exposes-perils-global-reliance-china-drug-supplies The spread of COVID-19 and the unprecedented…

China Dr Sharon Chan, head of JLABS @ Shanghai – the first JLABS presence in Asia-Pacific as well as the largest globally – shares how Johnson & Johnson is investing in the innovation ecosystem in China and the APAC region; some of the key milestones over the past year; and her…

China On March 30, 2020, the State Administration for Market Regulation (SAMR) enacted the Amended Drug Registration Regulation (DRR) as part of its efforts to strengthen and streamline its regulation of the pharmaceutical industry. The DRR seeks, on the one hand, to further confirm a series of changes made in drug…

China Alphamab Oncology and I-Mab Biopharma, two of China’s fastest-growing biotech firms, both bolstered by recent successful IPOs, are increasingly adapting their portfolio strategies to launch products on the large but challenging domestic Chinese market.   I-Mab: Observing Competitors and Staying Flexible I-Mab already has a fairly advanced China portfolio, with…